Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pulmatrix Inc PULM

Healthcare Biotechnology
Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious... see more

Recent & Breaking News (NDAQ:PULM)

Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets

PR Newswire May 15, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDUS, COOP, ICAD, PULM on Behalf of Shareholders

PR Newswire May 13, 2025

PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM

Business Wire May 9, 2025

Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets

PR Newswire March 21, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TGI, PULM, CCNE, TURN on Behalf of Shareholders

PR Newswire February 25, 2025

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pulmatrix, Inc. (PULM)

Newsfile February 24, 2025

PULM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pulmatrix, Inc. Is Fair to Shareholders

Business Wire February 19, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CDE, ALVR, PULM, ENTO on Behalf of Shareholders

PR Newswire November 21, 2024

Lifshitz Law PLLC Announces Investigations of LBRDA, LLYVA, PULM, and AE

ACCESS Newswire November 15, 2024

PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM

Business Wire November 14, 2024

PULM INVESTOR ALERT: Rigrodsky Law, P.A. Is Investigating Pulmatrix, Inc. Merger

ACCESS Newswire November 14, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM, ENTO, PIK, PFC on Behalf of Shareholders

ACCESS Newswire November 14, 2024

Shareholder Alert: Ademi LLP investigates whether Pulmatrix, Inc. is obtaining a Fair Price for its Public Shareholders

Business Wire November 13, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AE, LBRDA, PULM, ENTO on Behalf of Shareholders

PR Newswire November 13, 2024

PULM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pulmatrix, Inc. Is Fair to Shareholders

Business Wire November 13, 2024

Pulmatrix and Cullgen Announce Proposed Merger

PR Newswire November 13, 2024

Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update

PR Newswire November 8, 2024

Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update

PR Newswire August 13, 2024

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation

PR Newswire May 29, 2024

Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)

PR Newswire May 15, 2024